학술논문
The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting-A Nation-Wide Retrospective Analysis (RACER).
Document Type
Academic Journal
Author
Potocki PM; Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Cracow, Poland.; Wiśniowski R; Beskidzkie Centrum Onkologii, 43-300 Bielsko Biała, Poland.; Haus D; Oddział Onkologiczny, Wojewódzki Szpital Specjalistyczny, 59-220 Legnica, Poland.; Chowaniec Z; Department of Clinical Oncology, Lower Silesian Oncology Center, 53-413 Wroclaw, Poland.; Kozaczka M; 2nd Clinic of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie Memorial Cancer Center and National Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.; Kustra M; 2nd Clinic of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie Memorial Cancer Center and National Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.; Samborska-Plewicka M; 2nd Clinic of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie Memorial Cancer Center and National Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.; Szweda M; 2nd Clinic of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie Memorial Cancer Center and National Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.; Starzyczny-Słota D; Clinical and Experimental Oncology Department, Maria Skłodowska-Curie Memorial Cancer Center and National Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.; Michalik M; Oncological Ward, Independent Public Health Care Unit, Voivodeship Specialized Hospital No. 3, 44-200 Rybnik, Poland.; Słomian G; Oncological Ward, Independent Public Health Care Unit, Voivodeship Specialized Hospital No. 3, 44-200 Rybnik, Poland.; Lebiedzińska A; Department of Oncology, Collegium Medicum, University of Warmia and Mazury, 10-228 Olsztyn, Poland.; Department of Oncology and Immuno-Oncology, Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration Hospital, 10-228 Olsztyn, Poland.; Jonak-Olczyk N; Oncology Clinic, University Hospital, 31-501 Cracow, Poland.; Łaszewska-Kraińska N; Gdynia Oncology Centre of the Polish Red Cross Maritime Hospital, 81-519 Gdynia, Poland.; Adamowicz K; Department of Clinical Oncology, Pomeranian Hospitals, 81-519 Gdynia, Poland.; Kolenda P; Department of Clinical Oncology and Immuno-Oncology, Greater Poland Cancer Centre, 61-866 Poznań, Poland.; Drosik-Kwaśniewska A; Department of Clinical Oncology, Maria Sklodowska-Curie Memorial Cancer Center and National Institute of Oncology, Cracow Branch, 31-115 Cracow, Poland.; Szwiec M; Department of Surgery and Oncology, University of Zielona Góra, 65-064 Zielona Góra, Poland.; Dziura R; Department of Clinical Oncology, Holy Cross Cancer Center, 25-734 Kielce, Poland.; Czech J; Tadeusz Koszarowski Cancer Center in Opole, Department of Oncology with Daily Unit, 45-061 Opole, Poland.; Dąbrowska M; Department of Clinical Oncology, No. 4 Provincial Specialist Hospital, 41-902 Bytom, Poland.; Nowakowska-Zajdel E; Department of Clinical Oncology, No. 4 Provincial Specialist Hospital, 41-902 Bytom, Poland.; Department of Nutrition-Related Disease Prevention, Faculty of Health Sciences in Bytom, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.; Department of Metabolic Disease Prevention, Faculty of Health Sciences in Bytom, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.; Klank-Sokołowska E; Department of Clinical Oncology, Comprehensive Cancer Centre of Białystok, 15-027 Białystok, Poland.; Konopka K; Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Cracow, Poland.; Kwinta Ł; Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Cracow, Poland.; Dobrzańska J; Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Cracow, Poland.; Wysocki PJ; Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Cracow, Poland.
Source
Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2072-6694
Abstract
Anti-EGFR antibodies combined with chemotherapy doublets are a cornerstone of the upfront treatment of colorectal cancer. RAS and BRAF mutations are established negative predictive factors for such therapy. The primary tumour located in the proximal colon has recently emerged as another negative predictive factor. We have conducted a retrospective multicentre study to collect data on real-world population characteristics, practice patterns, and outcomes in patients with metastatic colorectal cancer treated in a first-line setting with either cetuximab or panitumumab in combination with either FOLFOX or FOLFIRI chemotherapy. The presented analysis focuses on the impact of the primary tumour location. 126 of 842 patients analysed (15.0%) had proximal primary. It was associated with a lower BMI at diagnosis, mucinous histology, and peritoneal metastases. It was also associated with inferior treatment outcomes in terms of response ratio: 59.4% vs. 74.22% (odds ratio [OR] 0.51, 95% CI 0.33-0.78, p = 0.010), and median depth of response: -36.7% vs. -50.0% ( p = 0.038). There was only a borderline non-significant trend for inferior PFS in patients with proximal tumours. OS data was incomplete. The presented analysis confirms the negative impact of tumour sidedness on the efficacy of an upfront anti-EGFR-chemotherapy combination and provides valuable data on real-world population characteristics.